logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study | Journal Article / Research | MSF Science Portal
Journal Article
|Research

The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study

Abongomera C, Diro EGJ, de Lima Pereira A, Buyze J, Stille K, van Griensven J, Ritmeijer KKD
Download

Similar Content
Loading...
Loading...
Loading...
Abstract
North-west Ethiopia faces the highest burden world-wide of visceral leishmaniasis (VL) and HIV co-infection. VL-HIV co-infected patients have higher (initial) parasitological failure and relapse rates than HIV-negative VL patients. Whereas secondary prophylaxis reduces the relapse rate, parasitological failure rates remain high with the available antileishmanial drugs, especially when administered as monotherapy. We aimed to determine the initial effectiveness (parasitologically-confirmed cure) of a combination of liposomal amphotericin B (AmBisome) and miltefosine for treatment of VL in HIV co-infected patients.

Countries

Ethiopia

Subject Area

tuberculosisHIV/AIDS

Languages

English
DOI
10.1371/journal.pntd.0006527
Published Date
25 May 2018
PubMed ID
29799869
Journal
PLOS Neglected Tropical Diseases
Volume | Issue | Pages
Volume 12, Issue 5
Issue Date
2018-05-25
Dimensions Badge